These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 37311835)

  • 21. Utilization of deep learning to quantify fluid volume of neovascular age-related macular degeneration patients based on swept-source OCT imaging: The ONTARIO study.
    Sodhi SK; Pereira A; Oakley JD; Golding J; Trimboli C; Russakoff DB; Choudhry N
    PLoS One; 2022; 17(2):e0262111. PubMed ID: 35157713
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Automated Quantification of Pathological Fluids in Neovascular Age-Related Macular Degeneration, and Its Repeatability Using Deep Learning.
    Mantel I; Mosinska A; Bergin C; Polito MS; Guidotti J; Apostolopoulos S; Ciller C; De Zanet S
    Transl Vis Sci Technol; 2021 Apr; 10(4):17. PubMed ID: 34003996
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Linking disease activity with optical coherence tomography angiography in neovascular age related macular degeneration using artificial intelligence.
    Schranz M; Bogunovic H; Deak G; Sadeghipour A; Reiter GS; Schmidt-Erfurth U
    Sci Rep; 2024 Aug; 14(1):19278. PubMed ID: 39164449
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials.
    Sharma S; Toth CA; Daniel E; Grunwald JE; Maguire MG; Ying GS; Huang J; Martin DF; Jaffe GJ;
    Ophthalmology; 2016 Apr; 123(4):865-75. PubMed ID: 26783095
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association between retinal thickness variation and visual acuity change in neovascular age-related macular degeneration.
    Cheong KX; Teo AWJ; Cheung CMG; Too IHK; Chakravarthy U; Teo KYC
    Clin Exp Ophthalmol; 2021 Jul; 49(5):430-438. PubMed ID: 33856734
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration.
    Simader C; Ritter M; Bolz M; Deák GG; Mayr-Sponer U; Golbaz I; Kundi M; Schmidt-Erfurth UM
    Ophthalmology; 2014 Jun; 121(6):1237-45. PubMed ID: 24684838
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Spatial Correspondence Between Intraretinal Fluid, Subretinal Fluid, and Pigment Epithelial Detachment in Neovascular Age-Related Macular Degeneration.
    Klimscha S; Waldstein SM; Schlegl T; Bogunovic H; Sadeghipour A; Philip AM; Podkowinski D; Pablik E; Zhang L; Abramoff MD; Sonka M; Gerendas BS; Schmidt-Erfurth U
    Invest Ophthalmol Vis Sci; 2017 Aug; 58(10):4039-4048. PubMed ID: 28813577
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.
    Dugel PU; Koh A; Ogura Y; Jaffe GJ; Schmidt-Erfurth U; Brown DM; Gomes AV; Warburton J; Weichselberger A; Holz FG;
    Ophthalmology; 2020 Jan; 127(1):72-84. PubMed ID: 30986442
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preliminary analysis of predicting the first recurrence in patients with neovascular age-related macular degeneration using deep learning.
    Jang B; Lee SY; Kim C; Park UC; Kim YG; Lee EK
    BMC Ophthalmol; 2023 Dec; 23(1):499. PubMed ID: 38062449
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy Outcomes of Brolucizumab Versus Aflibercept in Neovascular Age-Related Macular Degeneration Patients with Early Residual Fluid.
    Singh RP; Jhaveri C; Wykoff CC; Gale RP; Staurenghi G; Iida T; Koh A; B G; Gedif K; Singer M
    Ophthalmol Retina; 2022 May; 6(5):377-386. PubMed ID: 34968756
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Automated Segmentation of Lesions Including Subretinal Hyperreflective Material in Neovascular Age-related Macular Degeneration.
    Lee H; Kang KE; Chung H; Kim HC
    Am J Ophthalmol; 2018 Jul; 191():64-75. PubMed ID: 29655643
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A systematic evaluation of human expert agreement on optical coherence tomography biomarkers using multiple devices.
    Michl M; Neschi M; Kaider A; Hatz K; Deak G; Gerendas BS; Schmidt-Erfurth U
    Eye (Lond); 2023 Aug; 37(12):2573-2579. PubMed ID: 36577804
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pilot study to evaluate the role of high-dose ranibizumab 2.0 mg in the management of neovascular age-related macular degeneration in patients with persistent/recurrent macular fluid <30 days following treatment with intravitreal anti-VEGF therapy (the LAST Study).
    Fung AT; Kumar N; Vance SK; Slakter JS; Klancnik JM; Spaide RS; Freund KB
    Eye (Lond); 2012 Sep; 26(9):1181-7. PubMed ID: 22878451
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of intraretinal and subretinal fluid on clinical and anatomical outcomes in patients with neovascular age-related macular degeneration treated with bimonthly, treat-and-extend and as-needed ranibizumab in the In-Eye study.
    Saenz-de-Viteri M; Recalde S; Fernandez-Robredo P; López Gálvez MI; Arias Barquet L; Figueroa MS; García-Arumí J; García-Layana A;
    Acta Ophthalmol; 2021 Dec; 99(8):861-870. PubMed ID: 33720541
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Deep learning based joint segmentation and characterization of multi-class retinal fluid lesions on OCT scans for clinical use in anti-VEGF therapy.
    Hassan B; Qin S; Ahmed R; Hassan T; Taguri AH; Hashmi S; Werghi N
    Comput Biol Med; 2021 Sep; 136():104727. PubMed ID: 34385089
    [TBL] [Abstract][Full Text] [Related]  

  • 36. OCTA Biomarker Search in Patients with nAMD: Influence of Retinal Fluid on Time-Dependent Biomarker Response.
    Told R; Reumueller A; Schranz M; Brugger J; Weigert G; Reiter GS; Sacu S; Schmidt-Erfurth U
    Curr Eye Res; 2023 Jun; 48(6):600-604. PubMed ID: 36891909
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Non-neovascular age-related macular degeneration with subretinal fluid.
    Hilely A; Au A; Freund KB; Loewenstein A; Souied EH; Zur D; Sacconi R; Borrelli E; Peiretti E; Iovino C; Sugiura Y; Ellabban AA; Monés J; Waheed NK; Ozdek S; Yalinbas D; Thiele S; de Moura Mendonça LS; Lee MY; Lee WK; Turcotte P; Capuano V; Filali Ansary M; Chakravarthy U; Lommatzsch A; Gunnemann F; Pauleikhoff D; Ip MS; Querques G; Holz FG; Spaide RF; Sadda S; Sarraf D
    Br J Ophthalmol; 2021 Oct; 105(10):1415-1420. PubMed ID: 32920528
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Brolucizumab 12- and 16-Week Fixed Dosing Potential in Neovascular AMD: A post hoc Evaluation of Data from the HAWK and HARRIER Trials.
    Singer M; Khanani AM; Wolf A; Flores R; Chhablani J; B G; Clemens A; Gedif K; Liu X; Mulyukov Z; Querques G
    Ophthalmologica; 2022; 245(4):315-322. PubMed ID: 35344964
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cataract surgery in neovascular AMD: impact on visual acuity and disease activity.
    Tang HY; Rosén M; Granstam E
    BMC Ophthalmol; 2023 Jun; 23(1):276. PubMed ID: 37328798
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of Residual Retinal Fluid on Visual Function in Ranibizumab-Treated Neovascular Age-Related Macular Degeneration.
    Holekamp NM; Sadda S; Sarraf D; Guymer R; Hill L; Blotner S; Spicer G; Gune S
    Am J Ophthalmol; 2022 Jan; 233():8-17. PubMed ID: 34289338
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.